Page last updated: 2024-11-04

ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ether: A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ether : An organooxygen compound with formula ROR, where R is not hydrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

diethyl ether : An ether in which the oxygen atom is linked to two ethyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

platycodin D3: from the root of Platycodon grandiflorum (Campanulaceae); structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3283
CHEMBL ID16264
CHEBI ID35702
MeSH IDM0007827
PubMed CID75251137
MeSH IDM0007827

Synonyms (180)

Synonym
diethylaether
1,1'-oxybisethane
CHEBI:35702 ,
3-oxapentane
aether
aether pro narcosi
diethyl ether, contains 1 ppm bht as inhibitor, anhydrous, >=99.7%
ethoxyethane
etere etilico
dwuetylowy eter
ethyl oxide
diethyl oxide
solvent ether
ethane,1'-oxybis-
diaethylaether
pronarcol
nsc-100036
ether
wln: 2o2
oxyde d'ethyle
diethyl ether
anesthesia ether
ethyl ether
60-29-7
ether ethylique
anaesthetic ether
ether, ethyl
nsc100036
anesthetic ether
ethyl ether, tech.
1,1'-oxydiethane
inchi=1/c4h10o/c1-3-5-4-2/h3-4h2,1-2h
ethane, 1,1'-oxybis-
rcra waste no. u117
etere etilico [italian]
ether [jan]
diethyl ether [anaesthetics, volatile]
einecs 200-467-2
un1155
rcra waste number u117
hsdb 70
ai3-24233
diaethylaether [german]
oxyde d'ethyle [french]
nsc 100036
dwuetylowy eter [polish]
ether ethylique [french]
diethyl ether, anhydrous, acs reagent, >=99.0%, contains 1 ppm bht as inhibitor
ether (jp17/usp)
D01772
ether, diethyl
DIETHYLETHER ,
diethyl ether, puriss., dried over molecular sieve deperox dehydrat (h2o <=0.005%), >=99.8% (gc)
diethyl ether, puriss. p.a., acs reagent, >=99.8% (gc)
diethyl ether, spectrophotometric grade, >=99.9%, inhibitor-free
diethyl ether, puriss., dried over molecular sieve (h2o <=0.005%), >=99.8% (gc)
diethyl ether, purum, >=99.0% (gc)
D3479
ether, anhydrous
etherum
ether anaesthesicus
CHEMBL16264
anhydrous ether
0f5n573a2y ,
ether [usp:jan]
diethyl ether or ethyl ether [un1155] [flammable liquid]
ether anhydrous
unii-0f5n573a2y
ec 200-467-2
diethyl ether or ethyl ether
68890-94-8
69227-20-9
70131-58-7
69013-19-0
71011-10-4
AKOS015950740
et2o
FT-0624837
FT-0624836
FT-0624838
68890-95-9
ether [ii]
ether [vandf]
ether [ep monograph]
etherum [hpus]
ethyl ether [who-dd]
ethyl ether [mi]
ether [hsdb]
solvent ether [mart.]
ethyl ether [inci]
anaesthetic ether [who-ip]
ether anaesthesicus [who-ip latin]
ether [usp monograph]
ehtyl ether
di ethylether
ethoxy-ethane
di-ethylether
diethyether
diethyl-ether
2-ethoxyethane
(c2h5)2o
di ethyl ether
diethy ether
diethyi ether
etoet
ethyl ether-
dietyl ether
1,1' -oxybisethane
1,1'-oxy-bisethane
diehtyl ether
diethl ether
sulfuric ether
o(c2h5)2
ethyl-ether
dietylether
oet2
o(ch2ch3)2
o(et)2
monoethyl ether
di-ethyl ether
1,1'-oxybis ethane
ethyl ether anhydrous a.c.s.
1-ethoxyethane #
un 1155
mfcd00011646
DTXSID3021720 ,
diethyl ether, spectrophotometric grade
STL445704
diethyl ether, spectrophotometric grade, 99%, inhibitor free
diethylether (peptide grade)
diethyl ether, hplc grade
diethyl ether, anhydrous, acs, 99% min, stab. with bht
ethyl ether anhydrous stabilized with 5ppm of bht
diethyl ether, analytical standard
diethyl ether, anhydrous, acs reagent, >=99.0%, contains bht as inhibitor
diethyl ether, acs reagent, >=98.0%, contains ~2% ethanol and ~10ppm bht as inhibitor
diethyl ether, for hplc, >=99.9%, inhibitor-free
diethyl ether, for uv-spectroscopy, >=99.8% (gc)
diethyl ether, acs reagent, anhydrous, >=99.0%, contains 1 ppm bht as inhibitor
diethyl ether, puriss., meets analytical specification of ph.??eur., bp, >=99.5% (gc)
diethyl ether, reagent grade, >=98%, contains ~2% ethanol and ~10ppm bht as inhibitor
diethyl ether, jis special grade, >=99.5%
diethyl ether, >=99.5%
diethyl ether, contains bht as inhibitor, puriss. p.a., acs reagent, reag. iso, reag. ph. eur., >=99.8%
diethyl ether, acs reagent, anhydrous, >=99.0%, contains bht as inhibitor
diethyl ether, saj first grade, >=99.0%
diethyl ether, laboratory reagent, >=99.5% (gc)
ethyl ether, anhydrous, stabilized with bht, max water 50ppm
diethyl ether, anhydrous, 99.5%, ?50 ppm h2o
diethyl ether, p.a., 99.5%
diethyl ether, acs reagent, 99.5%
diethyl ether, lr, contains 5 ppm bht as stabilizer, >=99.5%
diethyl ether, pharmaceutical secondary standard; certified reference material
diethyl ether, p.a., 99.0%
diethyl ether, puriss., 99.0%, contains 0.0025% bht
diethyl ether, anhydrous, contains 5 ppm bht as stabilizer, >=99.5%
diethyl ether, uv hplc spectroscopic, 99.9%
diethyl ether, for hplc, contains 5 ppm bht as stabilizer, >=99%
diethyl ether, ar, contains 5 ppm bht as stabilizer, >=99.5%
diethyl ether, p.a., acs reagent, 99.5%, contains 0.0025% bht
ethane, 1,1'-oxybis
1-hydroperoxy-8-carboxyoctyl 3,4-epoxynon-(2e)-enyl ether
diethyl ether anhydrous acs grade stabilized with 5ppm of bht
DB13598
diethylether 100 microg/ml in acetonitrile
Q202218
1,1'-oxobis(ethane)
667919-88-2
diethyl ether (ethyl ether)
dtxcid101720
1,1'-oxybis(ethane)
platycodin d3
67884-03-1
HY-N3519
CS-0023697
FT-0775989
MS-32148
DTXSID001317737
E87127
AKOS040760640

Research Excerpts

Effects

The "Ether Day" has been portrayed in many ways. Ether has been replaced completely by newer inhalation agents. Poly-ether B has shown promise in the non-toxic inhibition of larval barnacle attachment.

ExcerptReferenceRelevance
"The "Ether Day" has been portrayed in many ways."( [From ether anesthesia to "green" anesthesia : Challenges in anesthesiology over the last 175 years].
Böhrer, H; Petermann, H; Witte, W, 2021
)
1.56
"Ether has been replaced completely by newer inhalation agents and open drop delivery systems have been exchanged for complicated vaporizers and monitoring systems."( Ether in the developing world: rethinking an abandoned agent.
Agarwal, N; Chang, CY; Goldstein, E; Swan, KG, 2015
)
2.58
"Poly-ether B has shown promise in the non-toxic inhibition of larval barnacle attachment."( Effects of poly-ether B on proteome and phosphoproteome expression in biofouling Balanus amphitrite cyprids.
Chandramouli, KH; Dash, S; Qian, PY; Zhang, Y, 2012
)
1.18

Actions

ExcerptReferenceRelevance
"The ether-induced increase in LH-RH content was not affected by pretreatment with pentobarbital; however, the increase was abolished in animals subjected to hypothalamic deafferentation."( The effects of pentobarbital and ether anesthesia on hypothalamic LH-RH in the rat.
Knigge, KM; Morris, M, 1976
)
1.02

Treatment

Ether treatment, ultraviolet light irradiation, heating, freezing, and thawing destroy the syncytia-inducing activity of BLV. Ether-treated cells catalyzed the formation of the remarkable A2pm-A2pm cross-linkage.

ExcerptReferenceRelevance
"Ether anesthesia treatment on diestrus 1 (D1) increased P4 serum levels."( The participation of the cholinergic system in regulating progesterone secretion through the ovarian-adrenal crosstalk varies along the estrous cycle.
Barco, AI; Chavira, R; Cruz, ME; Domínguez, R; Flores, A; Meléndez, G; Palafox, MT; Rodríguez, JO, 2005
)
1.05
"Ether treatment for 13 successive previous generations gave rise to changes in the spatiotemporal characteristics of the phenocopy response."( Bithorax phenocopy and pattern formation. I. Spatiotemporal characteristics of the phenocopy response.
Bolton, E; Ho, MW; Saunders, PT, 1983
)
0.99
"ETB, ether treated bacteria, from E. "( Murein biosynthesis in ether permeabilized Escherichia coli starting from early peptidoglycan precursors.
Maass, D; Pelzer, H, 1981
)
1.09
"Ether treatment was studied as a method of increasing the ability of type B influenza antigen to detect antibody by hemagglutination inhibition. "( Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test.
Maassab, HF; Monto, AS, 1981
)
3.15
"Ether treatment, ultraviolet light irradiation, heating, freezing, and thawing destroy the syncytia-inducing activity of BLV."( Induction of syncytia by the bovine C-type leukemia virus.
Diglio, CA; Ferrer, JF, 1976
)
0.98
"Ether-treated cells, however, were superior to the membrane preparation in catalyzing the formation of the remarkable A2pm-A2pm cross-linkage."( UDP-N-acetylmuramylpentapeptide as acceptor in murein biosynthesis in Escherichia coli membranes and ether-permeabilized cells.
Glauner, B; Höltje, JV; Kraus, W, 1985
)
1.21
"Ether-treated influenza B haemagglutination inhibition (HI) antigen was used in a study of serum collections from three different epidemic seasons. "( The HI test modified by ether treatment in the sero-epidemiological surveillance of influenza B.
Kleemola, M; Pyhälä, R; Visakorpi, R, 1985
)
2.02

Toxicity

2,2',4,4'-tetrabromodiphenyl ether (BDE-47) is one of the most important polybrominated diphenyl Ethers (PBDEs) congeners. Epidemiological studies have shown that it can cause adverse pregnancy outcomes.

ExcerptReferenceRelevance
"Experiments conducted with mice, rats and cats demonstrated ether-oxygen anesthesia to reduce the tolerance of the animals to strophanthin in the LD50 and MDL tests."( [Effect of ether-oxygen anesthesia and of the premedication agents on the toxicity and cardiotonic effect of strophanthin].
Gatsura, VV; Mitchenko, PP,
)
0.76
"Mice were given progressively smaller doses of carbon tetrachloride (CCl4) and at intervals later the LD50 of a second dose was determined."( Reduction of carbon tetrachloride toxicity by prior administration of a single small dose in mice and rats.
Lawson, TA; Pound, AW, 1975
)
0.25
") inoculation of 250 micrograms of DESL from GUH-2 dissolved in mineral oil was toxic to mice, resulting in weight loss and death of 100% of the animals (20/20) within 20 days."( Composition and toxicity of diethyl ether soluble lipids from Nocardia asteroides GUH-2 and Nocardia asteroides 10905.
Almeida, ET; Beaman, BL; Ioneda, T; Viscaya, L, 1993
)
0.56
"The present study was designed to investigate the adverse effects of indigenous Kamala seed etheral extract on various reproductive parameters of female rats."( An etheral extract of Kamala (Mallotus philippinensis (Moll.Arg) Lam.) seed induce adverse effects on reproductive parameters of female rats.
Chaube, SK; Singh, SP; Thakur, SC; Thakur, SS,
)
0.97
"To investigate the toxic effect and mechanism of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) in aquatic plants, in vivo and in vitro exposure to BDE-47 were conducted."( Toxic effects and mechanism of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) on Lemna minor.
Jiang, D; Meng, Y; Qiu, N; Sun, Y; Wang, R; Wang, X; Zhou, F, 2018
)
0.95
" However, its adverse effects on biota remain largely unknown."( Two-generational reproductive toxicity assessment of 6:2 chlorinated polyfluorinated ether sulfonate (F-53B, a novel alternative to perfluorooctane sulfonate) in zebrafish.
Cui, Q; Dai, J; Guo, H; Guo, Y; Pan, Y; Sheng, N; Shi, G; Wang, J, 2018
)
0.7
" The adverse effects of MTBE are largely attributed to its low boiling point, resulting in a tendency to evaporate."( Superior gallstone dissolubility and safety of tert-amyl ethyl ether over methyl-tertiary butyl ether.
Ahn, J; Cho, SJ; Choi, HJ; Hong, HE; Hong, TH; Hwang, KS; Jung, JK; Jung, KY; Kim, KH; Kim, OH; Kim, SJ; Lee, SC; Lee, TY; Park, JH; Seo, H; Song, JS; You, DD, 2019
)
0.75
" The neurodevelopmental toxic effects of PBDEs have been verified in previous studies, but the mechanisms are still unclear."( Behavioral change and transcriptomics reveal the effects of 2, 2', 4, 4'-tetrabromodiphenyl ether exposure on neurodevelopmental toxicity to zebrafish (Danio rerio) in early life stage.
Cai, Z; Huang, W; Liu, C; Wang, X; Wu, K; Wu, R; Xiao, J; Zheng, S, 2021
)
0.84
" This study confirmed that environmentally relevant levels of TBBPA and TBBPA-BDBPE are toxic to the liver."( Toxicity of Tetrabromobisphenol A and Its Derivative in the Mouse Liver Following Oral Exposure at Environmentally Relevant Levels.
Fu, J; Guo, H; Jiang, G; Li, D; Li, Z; Liu, Y; Luo, Q; Ma, J; Qu, G; Shi, J; Wang, Y; Wang, Z; Yang, X; Yao, L; Zhang, Q, 2021
)
0.62
" BDE-47 has been found to have toxic effects on bivalves, however, the immunotoxicity and the underlying mechanisms of BDE-47 on bivalves are not well understood yet."( In vitro immunotoxicity and possible mechanisms of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) on Ruditapes philippinarum hemocytes.
Liu, J; Zhou, S, 2022
)
0.95
"2, 2', 4, 4'-tetrabromodiphenyl ether (BDE-47) is one of the most important polybrominated diphenyl ethers (PBDEs) congeners, and epidemiological studies have shown that it can cause adverse pregnancy outcomes."( 2, 2', 4, 4'-tetrabromodiphenyl ether induces placental toxicity via activation of p38 MAPK signaling pathway in vivo and in vitro.
Cao, X; Fu, Z; Li, S; Liu, P; Liu, W; Xi, S; Zhou, Q, 2022
)
1.29
" These observed changes in developmental endpoints, hormonal level, and alteration in mRNA expression of component genes involved in neurodevelopmental pathways could be part of the possible mechanism of the observed toxic effects of TBBPA-DHEE exposure on zebrafish."( Transcriptomic sequencing reveals the potential molecular mechanism by which Tetrabromobisphenol A bis (2-hydroxyethyl ether) exposure exerts developmental neurotoxicity in developing zebrafish (Danio rerio).
Che, J; Chen, Y; Ding, Y; Feng, W; Mao, G; Okeke, ES; Qian, X; Wu, X; Xu, H; Zeng, Z, 2022
)
0.93
"Polybrominated biphenyl ethers (PBDEs) are new persistent pollutants that are widely exist in the environment and have many toxic effects."( Behavioral changes and transcriptomic effects at embryonic and post-embryonic stages reveal the toxic effects of 2,2',4,4'-tetrabromodiphenyl ether on neurodevelopment in zebrafish (Danio rerio).
Huang, W; Liu, C; Peng, J; Shi, X; Tan, W; Wu, K; Wu, R; Zhang, Q; Zheng, S, 2022
)
1.23

Pharmacokinetics

ExcerptReferenceRelevance
"In order to be able to use unanesthetized rats in pharmacokinetic studies it is necessary to find methods of drug administration and repeated blood sampling that do not stress the animals and therefore avoid possible alterations in the pharmacokinetic parameters caused by stress."( Use of rats chronically cannulated in the jugular vein and the duodenum in pharmacokinetic studies. Effect of ether anesthesia on absorption of amoxicillin.
Aristorena, JC; Chesa-Jiménez, J; García-Carbonell, MC; Granero, L; Peris, JE; Torres-Molina, F, 1996
)
0.51
" The method herein described was superior to previous methods in sensitivity and sample throughput and successfully applied to clinical pharmacokinetic study of venlafaxine sustained-release capsule in healthy male volunteers after oral administration."( Simultaneous quantification of venlafaxine and O-desmethylvenlafaxine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study.
Li, F; Li, N; Qin, F; Qin, T; Zhang, Y, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" Small molecule drugs containing a nitrogen that can be protonated to afford a formal +1 charge can interact with hERG to prevent the repolarization of outward rectifier currents."( New Insights into Ion Channels: Predicting hERG-Drug Interactions.
Wempe, MF, 2022
)
0.72

Bioavailability

An ether-lipid analogue of CDV, CMX001 (HDP-CDV), has potent antiviral activity against a range of DNA viruses including poxviruses. It has excellent oral bioavailability and minimal nephrotoxicity.

ExcerptReferenceRelevance
" Bioavailability of 1,1-DCE, as determined by comparing areas under blood concentration versus time curves (AUCs), was equivalent in animals given the same dose of 1,1-DCE iv and po."( Toxicokinetics and bioavailability of oral and intravenous 1,1-dichloroethylene.
Bruckner, JV; D'Souza, R; Desai, F; Feldman, S; Putcha, L, 1986
)
0.27
" An ether-lipid analogue of CDV, CMX001 (HDP-CDV), has potent antiviral activity against a range of DNA viruses including poxviruses, excellent oral bioavailability and minimal nephrotoxicity."( Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.
Almond, M; Buller, RM; Lampert, B; Oberle, C; Painter, G; Parker, S; Robertson, A; Touchette, E; Trost, LC, 2008
)
1.16
" One promising pyridine derivative (49) displayed 100% oral bioavailability in mice and delivered a 96% parasite burden reduction when dosed at 50 mg/kg in a Leishmania donovani mouse model of visceral leishmaniasis."( Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.
Braillard, S; Chatelain, E; Cooper, CB; Denny, WA; Franzblau, SG; Gupta, S; Launay, D; Ma, Z; Maes, L; Marshall, AJ; O'Connor, PD; Thompson, AM; Wan, B; Yardley, V, 2021
)
1.01
"There are conflicting findings over the bioavailability of long-chain n-3 polyunsaturated fatty acids (n-3 PUFA) from krill oil (KO) compared with fish oil (FO) in short- and long-term studies."( Enrichment of n-3 containing ether phospholipids in plasma after 30 days of krill oil compared with fish oil supplementation.
Sinclair, AJ; Su, XQ; Sung, HH, 2022
)
1.01
" However, studies on the bioavailability and transformation of PBDEs and their derivatives in soil organisms remain scarce."( Biotransformation kinetics and pathways of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) and its hydroxylated and methoxylated derivatives (6-OH-BDE-47 and 6-MeO-BDE-47) in earthworms (Eisenia fetida).
Li, Y; Wang, G; Xu, X; Zhang, Y, 2023
)
1.14
" Herein, hydroponic experiments indicate that FA and HA reduce the accumulation of an emerging PFAS of high concern, 6:2 chlorinated polyfluoroalkyl ether sulfonate (6:2 Cl-PFESA), in wheat roots by reducing its bioavailability in the solution."( Underlying Mechanisms for Low-Molecular-Weight Dissolved Organic Matter to Promote Translocation and Transformation of Chlorinated Polyfluoroalkyl Ether Sulfonate in Wheat.
Guo, J; Liang, X; Liu, S; Shen, L; Wang, T; Zhou, J; Zhu, L, 2022
)
1.12

Dosage Studied

A diet fortified with 2,2', 4,4'-tetrabromodiphenyl ether (BDE-47: 0, 10, 100, and 1000 ng/g) was dosed to 4-7-day-old post-hatch medaka fish for 40 days. Dexamethasone blocked the stress-induced prolactin release in a dosage dependent manner.

ExcerptRelevanceReference
" Ouabain dosage needed to cause ventricular tachycardia was significantly higher than that of pentobarbital with all agents except fluroxene, as was the LD50."( The effect of enflurane, isoflurane, fluroxene, methoxyflurane and diethyl ether anesthesia on ouabain tolerance in the dog.
Albrecht, RF; Cairoli, VJ; El-Etr, AA; Grossman, RK; Ivankovich, AD; Miletich, DJ,
)
0.36
" The dose-response curves in all anesthetics remained unaltered in the presence of either 3 x 10(-7) M dl-propranolol or 1 x 10(-6) M atropine."( Mechanisms of chronotropic effects of volatile inhalation anesthetics.
Krisna, G; Paradise, RR,
)
0.13
" This inhibitor was presumed to be calcitonin (CT) because: 1) the in vitro dose-response curve was parallel to that obtained with synthetic salmon CT; 2) the activity was eluted on Sephadex G-50 chromatography at a position similar to that for salmon CT; and 3) the material produced hypocalcemia in vivo in rats."( The detection of transmissible gastroenteritis viral antigens by immunodiffusion.
Bohac, J; Derbyshire, JB; Thorsen, J, 1975
)
0.25
" This difference was observed when thyrotropin was given intraperitoneally or intravenously and the slope of the dose-response curves to TRH showed a flattening of the curve of rats treated with ether and a steeper slope of response in animals anesthetized with pentobarbital."( Effects of ether and pentobarbital anesthesia on thyroid function in the rat.
Bray, GA; Ohtake, M, 1977
)
0.84
" Dexamethasone (31, 125 or 500 mug/kg) blocked the stress-induced prolactin release in a dosage dependent manner with the highest dose decreasing plasma prolactin to levels similar to those observed in rats not exposed to the ether stress."( Modification of stress-induced prolactin release by dexamethasone or adrenalectomy.
Harms, PG; Langlier, P; McCann, SM, 1975
)
0.44
" In addition, it would be advisable to study other dosage regimens in unprimed children with these SPVs."( Comparison of new triton X-100- and tween-ether-treated split-treated vaccines in children.
Bisberg, DS; Davis, WJ; Denning, CR; Ennis, FA; Gaerlan, PF; Gross, PA; Setia, U, 1981
)
0.53
" For the dosage of the vaccine by the hemagglutinin content in weight units (microgram) in the process of manufacture, the development of the national standard of this antigen is necessary."( [Standards of attenuated influenza vaccine].
Egorov, PA; Ishkil'din, IB; Pushkarev, MA; Vasiaev, AI; Veselov, SIu, 1982
)
0.26
" The effects of various isoniazid dosage regimens on the hepatic microsomal defluorination rates of enflurane were compared with those of several other ether anesthetics, and the conditions for production of maximal enflurane defluorination rates were determined."( Metabolism by rat hepatic microsomes of fluorinated ether anesthetics following isoniazid administration.
Mazze, RI; Rice, SA; Sbordone, L, 1980
)
0.71
"The dose-response relationship for vecuronium during anesthesia with the azeotropic mixture of halothane and diethyl ether (HE) (66 ml of halothane mixed with 34 ml of ether in the same bottle)/oxygen was compared with halothane/nitrous oxide/oxygen anesthesia."( Halothane-diethyl ether azeotrope anesthesia under primitive conditions: guidelines for neuromuscular blockade with vecuronium.
Bengtsson, M; Eriksson, LI; Kalman, SH; Lennmarken, C, 1993
)
0.83
" A rapid transformation of dosed Cl-6:2 PFESA was observed, with a hydrogen-substituted polyfluoroalkyl ether sulfonate (1H-6:2 PFESA) identified as the predominant product by a nontarget screening workflow."( Identification of Novel Hydrogen-Substituted Polyfluoroalkyl Ether Sulfonates in Environmental Matrices near Metal-Plating Facilities.
Jiang, G; Lin, Y; Liu, A; Ruan, T, 2017
)
0.91
"A diet fortified with 2,2', 4,4'-tetrabromodiphenyl ether (BDE-47: 0, 10, 100, and 1000 ng/g) was dosed to 4-7-day-old post-hatch medaka fish for 40 days to evaluate the effects on the swimming activity of fish using a miniaturized swimming flume."( Effects of dietary 2,2', 4,4'-tetrabromodiphenyl ether (BDE-47) exposure on medaka (Oryzias latipes) swimming behavior.
Beltrán, EM; Carbonell, G; Fernández Torija, C; González-Doncel, M; Rodríguez Martín, JA; Sastre, S, 2018
)
0.99
" The degradation rates of BDE47 increased as PAC-Pd/Fe nanoparticle dosage and temperature increased."( Enhanced solubilization and reductive degradation of 2,2',4,4'- tretrabromodiphenyl ether by PAC-Pd/Fe nanoparticles in the presence of surfactant.
Huang, G; Li, H; Wang, M, 2020
)
0.78
" The method was used to quantitate DMDEE in rat plasma, amniotic fluid and fetus samples from a dose range finding toxicology study in which dams were dosed via gavage with DMDEE from GD 6 at doses of 0 (control), 62."( Development of an Analytical Method for Quantitation of 2,2'-Dimorpholinodiethyl Ether (DMDEE) in Rat Plasma, Amniotic Fluid and Fetal Homogenate by UPLC-MS-MS for Determination of Gestational and Lactational Transfer in Rats.
Cunny, H; Fernando, RA; Hubbard, T; Roberts, G; Robinson, VG; Silinski, MAR; Uenoyama, T; Waidyanatha, S, 2021
)
0.85
" One promising pyridine derivative (49) displayed 100% oral bioavailability in mice and delivered a 96% parasite burden reduction when dosed at 50 mg/kg in a Leishmania donovani mouse model of visceral leishmaniasis."( Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.
Braillard, S; Chatelain, E; Cooper, CB; Denny, WA; Franzblau, SG; Gupta, S; Launay, D; Ma, Z; Maes, L; Marshall, AJ; O'Connor, PD; Thompson, AM; Wan, B; Yardley, V, 2021
)
1.01
" The results of restrictive cubic splines (RCS) showed that there were a nonlinear dose-response relationship between the exposure dose of BDE-153 and the expression levels of PPARγ, AMPKα, and adipokines."( 2,2',4,4',5,5'-Hexabromophenyl ether (BDE-153) causes abnormal insulin secretion and disorders of glucose and lipid metabolism in mice.
Fan, Y; Jiang, SR; Li, MY; Liu, ZL; Wang, JS; Wang, ML, 2023
)
1.2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
inhalation anaestheticnull
non-polar solventnull
refrigerantA substance used in a thermodynamic heat pump cycle or refrigeration cycle that undergoes a phase change from a gas to a liquid and back. Refrigerants are used in air-conditioning systems and freezers or refrigerators and are assigned a "R" number (by ASHRAE - formerly the American Society of Heating, Refrigerating and Air Conditioning Engineers), which is determined systematically according to their molecular structure.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
etherAn organooxygen compound with formula ROR, where R is not hydrogen.
volatile organic compoundAny organic compound having an initial boiling point less than or equal to 250 degreeC (482 degreeF) measured at a standard atmospheric pressure of 101.3 kPa.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID603950In-vitro air to lung partition coefficients of the compound, logK(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID168703Inhibition of Rana pipiens muscle activity.1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID603952In-vitro blood to lung partition coefficients of the compound, logP(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1134605Oil-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID162230The toxicity of compound was determined using Konemann's Industrial Pollutants Toxicity Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID101345Toxicity determined using Golden Orfe Fish Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID343683Octanol-water partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID26047logBB, log(C brain / C blood)1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Computation of brain-blood partitioning of organic solutes via free energy calculations.
AID23443Partition coefficient (logP)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID159270Toxicity determined using Microtox Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID212400Toxicity determined using Tadpole Narcosis Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID1134606Et2O-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID343684Alkane-water partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID603951In-vitro air to blood partition coefficients of the compound, logK(blood) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1525561Inhibition of human TASK1 expressed in African green monkey COS cells at 0.6 mM by whole cell patch clamp assay relative to control2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
TASK Channels Pharmacology: New Challenges in Drug Design.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,836)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902261 (58.94)18.7374
1990's346 (9.02)18.2507
2000's399 (10.40)29.6817
2010's447 (11.65)24.3611
2020's383 (9.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 152.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index152.18 (24.57)
Research Supply Index8.37 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index290.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (152.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials39 (0.91%)5.53%
Trials0 (0.00%)5.53%
Reviews72 (1.69%)6.00%
Reviews0 (0.00%)6.00%
Case Studies126 (2.95%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other4,029 (94.44%)84.16%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effectiveness of Polyether-Ether-Ketone (PEEK) as a Fixed Retainer Compared to Multistranded Stainless Steel Wires: A Randomized Clinical Trial [NCT05557136]40 participants (Anticipated)Interventional2022-09-03Recruiting
Evaluation of Esthetic and Biomechanical Outcome of Maxillary Anterior Single-Tooth Zirconia Implant Supported PEKK Crowns Versus Lithium Disilicate Crowns on PEKK Abutments: Randomized Controlled Trial [NCT03521024]10 participants (Anticipated)Interventional2018-09-15Not yet recruiting
A Multicentre Study Evaluating the Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Standard of Care in the Treatment of Severe Atopic Dermatitis, a Phase II Randomized, Clinical Trial [NCT03052348]78 participants (Anticipated)Interventional2017-11-01Not yet recruiting
Evaluation of Patient Satisfaction Using Autogenous Inlay (Sandwich) Eminoplasty Versus Patient Specific Poly Ether-ether Ketone (PEEK) Onlay Implant in Treatment of Chronic Condylar Dislocation A Randomized Control Trial [NCT03994692]7 participants (Anticipated)Interventional2019-06-20Not yet recruiting
Evaluation of Clinical Performance of 3D Printed Polyether Ether Ketone (PEEK) Inlays Compared With Milled Indirect PEEK Inlays Versus Indirect Resin Composite Inlays Over One Year Period of Time (A Randomized Clinical Trial) [NCT04532671]20 participants (Anticipated)Interventional2020-10-01Not yet recruiting
A Double-Blind, Placebo-Controlled, Phase 2, Responsive Adaptive Randomization Study of ORP-101 in Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D) [NCT04129619]Phase 2321 participants (Actual)Interventional2019-11-22Completed
A Randomized, Double-Blind, Vehicle-Controlled Ascending Multiple Dose and Clinical Proof-Of-Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis [NCT02655679]Phase 1/Phase 2104 participants (Actual)Interventional2015-12-15Completed
A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] [NCT00118222]Phase 31 participants (Actual)Interventional2005-03-31Completed
Evaluation of Using 3D Printed Polyether Ether Ether Ketone Facial Implants in Repairing Maxillofacial Deformities [NCT05348434]10 participants (Actual)Observational2020-02-25Completed
Validity of PEEK PSI Containing Autogenous Bone Graft for Maxillary Reconstruction Following Lesion Enucleation [NCT03265795]8 participants (Anticipated)Interventional2018-01-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02655679 (15) [back to overview]Number of Participants With Clinically Significant Changes in Clinical Laboratory Values
NCT02655679 (15) [back to overview]Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values
NCT02655679 (15) [back to overview]Number of Participants With Clinically Significant Changes in Vital Signs
NCT02655679 (15) [back to overview]Number of Participants With Treatment-related Adverse Events (AEs)
NCT02655679 (15) [back to overview]Percentage Change From Baseline Eczema Area and Severity Index (EASI)
NCT02655679 (15) [back to overview]Percentage Change From Baseline in Investigator Global Assessments (IGA) Score
NCT02655679 (15) [back to overview]Percentage Change From Baseline in Pruritus VAS Score
NCT02655679 (15) [back to overview]Percentage Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score
NCT02655679 (15) [back to overview]Percentage Change From Baseline in Total Body Surface Area (BSA)
NCT02655679 (15) [back to overview]Percentage Change From Baseline in VAS Sleep Score
NCT02655679 (15) [back to overview]Area Under the Plasma Concentration Versus Time Curve, From Time 0 to 12 Hours (AUC0-12hr) for VTP-38543
NCT02655679 (15) [back to overview]Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUClast) for VTP-38543
NCT02655679 (15) [back to overview]Elimination Half-life (t½) for VTP-38543
NCT02655679 (15) [back to overview]Maximum Plasma Concentration (Cmax) for VTP-38543-001
NCT02655679 (15) [back to overview]Time to Maximum Plasma Concentrations (Tmax) for VTP-38543

Number of Participants With Clinically Significant Changes in Clinical Laboratory Values

Clinical Laboratory tests included chemistry, hematology and urinalysis tests collected during the study. The investigator determined if the changes in laboratory results were clinically significant. (NCT02655679)
Timeframe: Baseline (Day 0) to Day 35

InterventionParticipants (Count of Participants)
VTP-38543 0.05%0
VTP-38543 0.15%1
Vehicle Without Transcutol®P0
VTP-38543 1%0
Vehicle With Transcutol®P0

[back to top]

Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values

A standard 12-lead ECG was performed. The investigator determined if the changes in ECG results were clinically significant. (NCT02655679)
Timeframe: Baseline (Day 0) to Day 35

InterventionParticipants (Count of Participants)
VTP-38543 0.05%0
VTP-38543 0.15%0
Vehicle Without Transcutol®P0
VTP-38543 1%0
Vehicle With Transcutol®P0

[back to top]

Number of Participants With Clinically Significant Changes in Vital Signs

Vital signs included blood pressure, pulse, respiration rate and body temperature. The investigator determined if the changes in vital sign results were clinically significant. (NCT02655679)
Timeframe: Baseline (Day 0) to Day 35

InterventionParticipants (Count of Participants)
VTP-38543 0.05%0
VTP-38543 0.15%0
Vehicle Without Transcutol®P0
VTP-38543 1%0
Vehicle With Transcutol®P0

[back to top] [back to top]

Percentage Change From Baseline Eczema Area and Severity Index (EASI)

The investigator assessed four body regions: Head and neck, Upper extremities, Trunk including axillae and groin, and Lower extremities including buttocks. Each body region was scored based on BSA where 0=No involvement to 6=90-100%. Each body region was assessed for erythema, infiltration/papulation, excoriation and lichenification using a 4-point scale where 0=None to 3=Severe. EASI total score was determined by combining the individual scores for each of the 4 body regions. The total for each region was calculated by [erythema + infiltration+ excoriation + lichenification * area involvement * a constant (constants Head and Neck=0.1, Upper Limbs=0.2, Trunk=0.3, Lower Limbs=0.4)]. The EASI total score was determined by combining the individual scores for each of the 4 body regions for a total possible score of 0 (best) to 72 (worst). A negative percentage change indicates improvement. (NCT02655679)
Timeframe: Baseline (Day 0) to Day 28

Interventionpercentage change in EASI (Mean)
VTP-38543 0.05%-36.26
VTP-38543 0.15%-9.16
Vehicle Without Transcutol®P-26.99
VTP-38543 1%-12.52
Vehicle With Transcutol®P-27.10

[back to top]

Percentage Change From Baseline in Investigator Global Assessments (IGA) Score

The investigator assessed the participant's atopic dermatitis using the 5-point IGA where 0=clear (Minor, residual discoloration, no erythema or induration/papulation, no oozing/crusting) to 4=Severe disease (Deep/bright red erythema with severe induration/papulation with oozing/crusting). A negative percentage change indicates improvement. (NCT02655679)
Timeframe: Baseline (Day 0) to Day 28

Interventionpercentage change in IGA score (Mean)
VTP-38543 0.05%-12.7
VTP-38543 0.15%-16.7
Vehicle Without Transcutol®P-19.4
VTP-38543 1%-6.1
Vehicle With Transcutol®P-13.2

[back to top]

Percentage Change From Baseline in Pruritus VAS Score

The participant used a 10-point VAS to assess the occurrence of pruritus (itchy skin) over the last 3 days where 0= None to 10=Worst Imaginable for a total possible score of 0 to 10. A negative percentage change indicates improvement. (NCT02655679)
Timeframe: Baseline (Day 0) to Day 28

Interventionpercentage change in pruritis VAS score (Mean)
VTP-38543 0.05%4.20
VTP-38543 0.15%-20.07
Vehicle Without Transcutol®P-26.75
VTP-38543 1%-25.80
Vehicle With Transcutol®P-34.68

[back to top]

Percentage Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score

The investigator assessed severity of atopic dermatitis (AD) using scoring atopic dermatitis (SCORAD) score obtained from different individual scales. 6-items: erythema, edema/papulation, oozing/crusts, excoriation, lichenification, and dryness were graded on a 4-point scale where 0=Absent to 3=Severe. The individual scores were added together to get a score of 0 to 18 that was multiplied by 3.5 for a score of 0 to 63. The overall BSA affected by AD (0 to 100 %) was divided by 5 for a score 0 to 20. The participant used a 10-point Visual Analog Scale (VAS) to evaluate loss of sleep and the occurrence of pruritus averaged over the last 3 days where 0=None to Worst Imaginable. The sum of the 2 VAS scores was 0 to 20. The above measures were added together for a total possible SCORAD score of 0 (best) to 103 (worst). A negative percentage change indicates improvement. (NCT02655679)
Timeframe: Baseline (Day 0) to Day 28

Interventionpercentage change in SCORAD score (Mean)
VTP-38543 0.05%-23.473
VTP-38543 0.15%-17.300
Vehicle Without Transcutol®P-24.453
VTP-38543 1%-14.483
Vehicle With Transcutol®P-18.630

[back to top]

Percentage Change From Baseline in Total Body Surface Area (BSA)

Percent BSA was estimated using the palmar surface of the participant's hand up to the proximal interphalangeal joint, including the thumb, to approximate 1% of the participant's BSA. The overall BSA affected by atopic dermatitis was evaluated from 0 to 100% and divided by 5 for a maximum of 20. A negative percentage change indicates improvement. (NCT02655679)
Timeframe: Baseline (Day 0) to Day 28

Interventionpercentage change in total BSA (Mean)
VTP-38543 0.05%-39.09
VTP-38543 0.15%-9.46
Vehicle Without Transcutol®P-17.39
VTP-38543 1%-9.44
Vehicle With Transcutol®P-28.51

[back to top]

Percentage Change From Baseline in VAS Sleep Score

The participant used a 10-point VAS to evaluate loss of sleep averaged over the last 3 days where 0= None to 10=Worst imaginable for a total possible score of 0 to 10. A negative percentage change indicates improvement. (NCT02655679)
Timeframe: Baseline (Day 0) to Day 28

Interventionpercentage change in VAS sleep score (Mean)
VTP-38543 0.05%-29.40
VTP-38543 0.15%-19.74
Vehicle Without Transcutol®P2.73
VTP-38543 1%-29.98
Vehicle With Transcutol®P-30.85

[back to top]

Area Under the Plasma Concentration Versus Time Curve, From Time 0 to 12 Hours (AUC0-12hr) for VTP-38543

(NCT02655679)
Timeframe: Day 0 (pre-dose, 1, 2, 4, 6, 9, and 12 hours post first dose), and Day 27 (pre-dose, 1, 2, 4, 6, 9, 12, 24, 48, and 72 hours post last dose)

,,
Interventionng*hr/mL (Mean)
Day 0Day 27
VTP-38543 0.05%2.2723.6
VTP-38543 0.15%1.3522.2
VTP-38543 1%20.0144

[back to top]

Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUClast) for VTP-38543

(NCT02655679)
Timeframe: Day 0 (pre-dose, 1, 2, 4, 6, 9, and 12 hours post first dose), and Day 27 (pre-dose, 1, 2, 4, 6, 9, 12, 24, 48, and 72 hours post last dose)

,,
Interventionng*hr/mL (Mean)
Day 0Day 27
VTP-38543 0.05%2.27129
VTP-38543 0.15%1.35104
VTP-38543 1%20.0720

[back to top]

Elimination Half-life (t½) for VTP-38543

(NCT02655679)
Timeframe: Day 0 (pre-dose, 1, 2, 4, 6, 9, and 12 hours post first dose), and Day 27 (pre-dose, 1, 2, 4, 6, 9, 12, 24, 48, and 72 hours post last dose)

,,
Interventionhour (Mean)
Day 0Day 27
VTP-38543 0.05%NA58.6
VTP-38543 0.15%NA47.2
VTP-38543 1%NA246

[back to top]

Maximum Plasma Concentration (Cmax) for VTP-38543-001

(NCT02655679)
Timeframe: Day 0 (pre-dose, 1, 2, 4, 6, 9, and 12 hours post first dose), and Day 27 (pre-dose, 1, 2, 4, 6, 9, 12, 24, 48, and 72 hours post last dose)

,,
Interventionng/mL (Mean)
Day 0Day 27
VTP-38543 0.05%0.5462.81
VTP-38543 0.15%0.2212.28
VTP-38543 1%2.3413.4

[back to top]

Time to Maximum Plasma Concentrations (Tmax) for VTP-38543

(NCT02655679)
Timeframe: Day 0 (pre-dose, 1, 2, 4, 6, 9, and 12 hours post first dose), and Day 27 (pre-dose, 1, 2, 4, 6, 9, 12, 24, 48, and 72 hours post last dose)

,,
Interventionhour (Median)
Day 0Day 27
VTP-38543 0.05%5.51
VTP-38543 0.15%96.5
VTP-38543 1%44

[back to top]